5,7-Dihydroxy-4-oxo-1,2,3,4-tetrahydrochinolin | 65510-97-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5,7-Dihydroxy-4-oxo-1,2,3,4-tetrahydrochinolin
• 英文别名: 5,7-dihydroxy-4-oxo-1,2,3,4-tetrahydroquinoline；5,7-dihydroxy-2,3-dihydro-1H-quinolin-4-one
• CAS: 65510-97-6
• 化学式: C₉H₉NO₃
• 分子量: 179.175
• InChiKey: NHWIQGVRRDRSPD-UHFFFAOYSA-N

物化性质

• 沸点：
  464.9±40.0 °C(Predicted)
• 密度：
  1.425±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5,7-Dihydroxy-4-oxo-1,2,3,4-tetrahydrochinolin 、 2-溴庚烷 生成 dl-5-Hydroxy-7-(2-heptyloxy)-4-oxo-1,2,3,4-tetrahydrochinolin
  参考文献：
  名称：

  JOHNSON, M. R.

  摘要：

  DOI：
• 作为产物：
  描述：

  1-Carbethoxy-5,7-dimethoxy-4-oxo-1,2,3,4-tetrahydrochinolin 生成 5,7-Dihydroxy-4-oxo-1,2,3,4-tetrahydrochinolin
  参考文献：
  名称：

  JOHNSON, M. R.

  摘要：

  DOI：

文献信息

• Oximino-1-hydroxyoctahydrobenzo[c]quinolines and derivatives thereof
  申请人：Pfizer Inc.

  公开号：US04309545A1

  公开（公告）日：1982-01-05

  9-Amino-1-hydroxyoctahydrobenzo[c]quinoline derivatives of formula ##STR1## and pharmaceutically acceptable acid addition salts thereof wherein R is hydrogen, COR.sub.7 or SO.sub.2 R.sub.8 where R.sub.7 is hydrogen, alkyl, having from one to five carbon atoms; alkenyl and alkynyl each having from two to six carbon atoms; trifluoromethyl, benzyl, furyl, thienyl, pyridyl or R.sub.9 C.sub.6 H.sub.4 where R.sub.9 is H, NH.sub.2, F, Cl, Br, CH.sub.3 or OCH.sub.3 ; R.sub.8 is alkyl having from one to five carbon atoms or R.sub.9 C.sub.6 H.sub.4 ; R.sub.1 is hydrogen, benzyl, benzoyl, alkanoyl having from one to five carbon atoms or --CO--(CH.sub.2).sub.p --NR.sub.2 R.sub.3 wherein p is 0 or an integer from 1 to 4; each of R.sub.2 and R.sub.3 when taken individually is hydrogen or alkyl having from one to four carbon atoms; R.sub.2 and R.sub.3 when taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic ring selected from piperidino, pyrrolo, pyrrolidino, morpholino or N-alkylpiperazino having from one to four carbon atoms in the alkyl group; R.sub.4 is hydrogen, alkyl having from 1 to 6 carbon atoms or --(CH.sub.2).sub.z --C.sub.6 H.sub.5 wherein z is an integer from 1 to 4; R.sub.5 is hydrogen, methyl or ethyl; R.sub.6 is hydrogen, --(CH.sub.2).sub.y -carbalkoxy having from one to four carbon atoms in the alkoxy group and wherein y is 0 or an integer from 1 to 4, carbobenzyloxy, formyl, alkanoyl having from two to five carbon atoms, alkyl having from one to six carbon atoms; --(CH.sub.2).sub.x --C.sub.6 H.sub.5 wherein x is an integer from 1 to 4; or --CO(CH.sub.2).sub.x-1 --C.sub.6 H.sub.5 ; Z is (a) alkylene having from one to nine carbon atoms; (b) -(alk.sub.1).sub.m -X-(alk.sub.2).sub.n - wherein each of (alk.sub.1) and (alk.sub.2) is alkylene having from one to nine carbon atoms, with the proviso that the summation of carbon atoms in (alk.sub.1) plus (alk.sub.2) is not greater than nine; each of m and n is 0 or 1; X is O, S, SO and SO.sub.2 ; and W is hydrogen, methyl, pyridyl, piperidyl, ##STR2## wherein W.sub.1 is selected from the group consisting of hydrogen, fluoro and chloro; and ##STR3## wherein W.sub.2 is hydrogen or ##STR4## is an integer from 1 to 5 and b is 0 or an integer from 1 to 5; with the proviso that the sum of a and b is not greater than 5; useful in mammals as analgesics, tranquilizers, antiemetic agents, diuretics, anticonvulsants, antidiarrheals, antitussives, in treatment of glaucoma, and intermediates therefore.

  式子如下：##STR1## 其中，R为氢、COR.sub.7或SO.sub.2 R.sub.8，其中R.sub.7为氢、烷基（含有1至5个碳原子）、烯基和炔基（每个含有2至6个碳原子）、三氟甲基、苄基、呋喃基、噻吩基、吡啶基或R.sub.9 C.sub.6 H.sub.4，其中R.sub.9为H、NH.sub.2、F、Cl、Br、CH.sub.3或OCH.sub.3；R.sub.8为烷基（含有1至5个碳原子）或R.sub.9 C.sub.6 H.sub.4；R.sub.1为氢、苄基、苯甲酰基、烷酰基（含有1至5个碳原子）或--CO--(CH.sub.2).sub.p --NR.sub.2 R.sub.3，其中p为0或1至4的整数；当R.sub.2和R.sub.3分别独立取氢或烷基（含有1至4个碳原子）时，R.sub.2和R.sub.3结合到它们所连接的氮上形成5-或6-成员的杂环，所选杂环为哌啶基、吡咯基、吡咯啉基、吗啉基或N-烷基哌嗪基，其中烷基中的碳原子数为1至4；R.sub.4为氢、烷基（含有1至6个碳原子）或--(CH.sub.2).sub.z --C.sub.6 H.sub.5，其中z为1至4的整数；R.sub.5为氢、甲基或乙基；R.sub.6为氢、--(CH.sub.2).sub.y-羧基烷氧基（烷氧基中含有1至4个碳原子，y为0或1至4的整数）、羧苄氧基、甲酰基、烷酰基（含有2至5个碳原子）、烷基（含有1至6个碳原子）、--(CH.sub.2).sub.x --C.sub.6 H.sub.5，其中x为1至4的整数；或--CO(CH.sub.2).sub.x-1 --C.sub.6 H.sub.5；Z为（a）含有1至9个碳原子的烷基；（b）-(alk.sub.1).sub.m -X-(alk.sub.2).sub.n-，其中每个（alk.sub.1）和（alk.sub.2）为含有1至9个碳原子的烷基，但有以下限制：（alk.sub.1）加（alk.sub.2）中碳原子的总和不大于9；m和n各自为0或1；X为O、S、SO和SO.sub.2；W为氢、甲基、吡啶基、哌啶基、##STR2## 其中W.sub.1选自由氢、氟或氯；以及##STR3## 其中W.sub.2为氢或##STR4## 为1至5的整数，b为0或1至5的整数；但有以下限制：a和b的总和不大于5；该化合物可用作哺乳动物的镇痛剂、镇静剂、抗恶心剂、利尿剂、抗癫痫剂、抗腹泻剂、止咳剂、治疗青光眼的药物及其中间体。
• 9-Amino-1-hydroxyoctahydrobenzo[c]quinolines and derivatives thereof as
  申请人：Pfizer Inc.

  公开号：US04351833A1

  公开（公告）日：1982-09-28

  9-Amino-1-hydroxyoctahydrobenzo[c]quinoline derivatives of formula ##STR1## and pharmaceutically acceptable acid addition salts thereof wherein R is hydrogen, COR.sub.7 or SO.sub.2 R.sub.8 where R.sub.7 is hydrogen, alkyl, having from one to five carbon atoms; alkenyl and alkynyl each having from two to six carbon atoms; trifluoromethyl, benzyl, furyl, thienyl, pyridyl or R.sub.9 C.sub.6 H.sub.4 where R.sub.9 is H, NH.sub.2, F, Cl, Br, Ch.sub.3 or OCH.sub.3 ; R.sub.8 is alkyl having from one to five carbon atoms or R.sub.9 C.sub.6 H.sub.4 ; R.sub.1 is hydrogen, benzyl, benzoyl, alkanoyl having from one to five carbon atoms or --CO--(CH.sub.2).sub.p --NR.sub.2 R.sub.3 wherein p is 0 or an integer from 1 to 4; each of R.sub.2 and R.sub.3 when taken individually is hydrogen or alkyl having from one to four carbon atoms; R.sub.2 and R.sub.3 when taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic ring selected from piperidino, pyrrolo, pyrrolidino, morpholino or N-alkylpiperazino having from one to four carbon atoms in the alkyl group; R.sub.4 is hydrogen, alkyl having from 1 to 6 carbon atoms or --(CH.sub.2).sub.z --C.sub.6 H.sub.5 wherein z is an integer from 1 to 4; R.sub.5 is hydrogen, methyl or ethyl; R.sub.6 is hydrogen, --(CH.sub.2).sub.y --carbalkoxy having from one to four carbon atoms in the alkoxy group and wherein y is 0 or an integer from 1 to 4, carbobenzyloxy, formyl, alkanoyl having from two to five carbon atoms, alkyl having from one to six carbon atoms; --(CH.sub.2).sub.x --C.sub.6 H.sub.5 wherein x is an integer from 1 to 4; or --CO(CH.sub.2).sub.x-1 --C.sub.6 H.sub.5 ; Z is (a) alkylene having from one to nine carbon atoms; (b) -(alk.sub.1).sub.m --X--(alk.sub.2).sub.n -- wherein each of (alk.sub.1) and (alk.sub.2) is alkylene having from one to nine carbon atoms, with the proviso that the summation of carbon atoms in (alk.sub.1) plus (alk.sub.2) is not greater than nine; each of m and n is 0 or 1; X is O, S, SO and SO.sub.2 ; and W is hydrogen, methyl, pyridyl, piperidyl, ##STR2## wherein W.sub.1 is selected from the group consisting of hydrogen, fluoro and chloro; and ##STR3## wherein W.sub.2 is hydrogen or ##STR4## a is an integer from 1 to 5 and b is 0 or an integer from 1 to 5; with the proviso that the sum of a and b is not greater than 5; useful in mammals as analgesics, tranquilizers, anti-emetic agents, diuretics, anticonvulsants, antidiarrheals, antitussives, in treatment of glaucoma, and intermediates therefore.

  公式为 ##STR1## 的9-氨基-1-羟基八氢苯并[c]喹啉衍生物及其药学上可接受的酸盐，其中R为氢、COR.sub.7或SO.sub.2R.sub.8，其中R.sub.7为氢、烷基（其中烷基中的碳原子数为1至5）、烯基和炔基（其中烯基和炔基中的碳原子数为2至6）、三氟甲基、苄基、呋喃基、噻吩基、吡啶基或R.sub.9C.sub.6H.sub.4，其中R.sub.9为H、NH.sub.2、F、Cl、Br、Ch.sub.3或OCH.sub.3；R.sub.8为烷基（其中烷基中的碳原子数为1至5）或R.sub.9C.sub.6H.sub.4；R.sub.1为氢、苄基、苯甲酰基、烷酰基（其中烷酰基中的碳原子数为1至5）或--CO--(CH.sub.2).sub.p--NR.sub.2R.sub.3，其中p为0或1至4的整数；R.sub.2和R.sub.3分别为氢或烷基（其中烷基中的碳原子数为1至4）；当R.sub.2和R.sub.3与它们所连接的氮一起形成5-或6-成员杂环环时，所述杂环环为哌啶基、吡咯基、吡咯啉基、吗啉基或N-烷基哌嗪基，其中烷基中的碳原子数为1至4；R.sub.4为氢、烷基（其中烷基中的碳原子数为1至6）或--(CH.sub.2).sub.z--C.sub.6H.sub.5，其中z为1至4的整数；R.sub.5为氢、甲基或乙基；R.sub.6为氢、--(CH.sub.2).sub.y--羧基烷氧基，其中烷氧基中的碳原子数为1至4，且y为0或1至4的整数，羧苄氧基、甲酰基、烷酰基（其中烷酰基中的碳原子数为2至5）、烷基（其中烷基中的碳原子数为1至6）、--(CH.sub.2).sub.x--C.sub.6H.sub.5，其中x为1至4的整数；或--CO(CH.sub.2).sub.x-1--C.sub.6H.sub.5；Z为（a）烷基（其中烷基中的碳原子数为1至9）；（b）-(alk.sub.1).sub.m--X--(alk.sub.2).sub.n--，其中每个（alk.sub.1）和（alk.sub.2）均为烷基（其中烷基中的碳原子数为1至9），但须满足（alk.sub.1）加（alk.sub.2）中的碳原子总数不大于9；每个m和n均为0或1；X为O、S、SO和SO.sub.2；W为氢、甲基、吡啶基、哌啶基、##STR2## 其中W.sub.1为选择自羟基、氟或氯的群；以及##STR3## 其中W.sub.2为氢或##STR4## a为1至5的整数，b为0或1至5的整数；但a和b的总和不大于5；可用于哺乳动物的镇痛剂、镇静剂、抗恶心剂、利尿剂、抗癫痫剂、止泻剂、止咳剂、治疗青光眼，以及其中间体。
• 9-Amino-1-hydroxyoctahydrobenzo(c)quinolines and derivatives thereof
  申请人：PFIZER INC.

  公开号：EP0045171B1

  公开（公告）日：1985-02-13
• US4260764A
  申请人：——

  公开号：US4260764A

  公开（公告）日：1981-04-07
• US4309545A
  申请人：——

  公开号：US4309545A

  公开（公告）日：1982-01-05